Obesity

A Delhi High Court has declined Novo Nordisk’s bid to halt Reddy’s ongoing production, allowing exports while patent validity proceeds to trial.

AstraZeneca, Lilly, Novo Nordisk and Amgen all moved up in the rankings on the Scrip 100 leaderboard powered by impressive double-digit growth.

The company announced positive Phase II results for tradipitant among patients taking Wegovy, enabling them to move more quickly to a therapeutic dose, when patients normally need to titrate.

Against a choppy macro backdrop, innovation dynamics have remained largely intact, as the industry continues to invest heavily into R&D.

Novo Nordisk’s deal with Emcure for semaglutide will launch Poviztra as a second obesity brand in India, improving access to weight loss treatments following a Lilly-Cipla deal for tirzepatide and seems a clever counter to Indian majors planning to launch generic semaglutide next year

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.

Alteogen's preparations to move its stock listing, ABL Bio's injection of funds into its US subsidiary to progress clinical trials and Ensol's plans for a Phase III trial of its osteoarthritis contender are among key recent developments in Korean biotech.

Amgen has worked its way through biosimilar and generic competitors for key drugs, with Prolia and Xgeva now challenged, and may have a mega-blockbuster on its hands in obesity.

Pfizer filed another lawsuit to halt Novo Nordisk’s attempt to acquire obesity drug developer Metsera instead of the US big pharma. Novo said Pfizer’s legal actions are “without merit” and “desperate.”

Dr. Reddy's doesn’t fully rule out "queries" from the Canadian regulator for generic semaglutide, though it is confident of selling “all its capacity” for the GLP-1 across target markets. A backup CMO site in the US for abatacept is expected to mitigate risks amid tariff and other uncertainties.

Hanmi is planning to file for Korean approval of the country's first homegrown obesity contender efpeglenatide by year-end, following positive topline Phase III data for the Sanofi U-turned asset.

A new report highlighting 62 key drug launches expected in 2026 includes five products that are predicted to hit a golden trifecta of being a first launch, having practice-changing potential and the promise of being a blockbuster.